Back to Search Start Over

Percentage of faecal excretion of meloxicam in the Cape vultures (Gyps corprotheres).

Authors :
Adawaren, Emmanuel Oluwasegun
Mukandiwa, Lillian
Chipangura, John
Wolter, Kerri
Naidoo, Vinny
Source :
Comparative Biochemistry & Physiology Part C: Toxicology & Pharmacology. Jan2019, Vol. 215, p41-46. 6p.
Publication Year :
2019

Abstract

Abstract Asian Gyps vulture species are gradually recovering from the devastating effect of diclofenac being present in contaminated carcasses. This drug was responsible for the death of over 10 million vultures in India, Nepal and Pakistan. To prevent the extinction of vultures, meloxicam was introduced after the ban of veterinary diclofenac. Meloxicam's safety in vultures was attributed to its short elimination half-life in contrast with diclofenac. The reason for the rapid elimination of meloxicam is yet to be explained. The aim of this study was to evaluate the role of biotransformation in the elimination of meloxicam. Six Cape griffon vultures (Gyps coprotheres) were treated with 2 mg/kg meloxicam intramuscularly for faecal and plasma quantification of meloxicam concentration over time. In the plasma meloxicam was characterised by a half-life, mean residence time, clearance and volume of distribution at steady state of 0.37 ± 0.10 h, 0.90 ± 0.12 h, 0.02 ± 0.00 l/h kg and 0.02 ± 0.00 l/kg respectively (presented as geometric mean). Over the 24 h monitoring period, the total non-metabolised meloxicam in the faeces was 1.35 ± 0.71% of the total concentration in the plasma. Based on the short meloxicam elimination half-life and low cumulative concentration of total faecal meloxicam over a period in excess of 10 half-lives, this study indicates that Cape griffon vultures are efficient metaboliser of meloxicam, which is suggestive of different set of cytochrome enzymes being involved in the metabolism to that for diclofenac in this species. Identification of orthologous human CYP2C9 and CYP3A4 enzyme families in vultures will be an important further step in explaining the differences in the metabolic pathway(s) of meloxicam and diclofenac for the species. Highlights • Develop and validate a high performance liquid chromatography (HPLC) for the quantification of meloxicam in vulture faeces. • Evaluate pharmacokinetic parameter of meloxicam in Cape vulture 10 h post administration using HPLC. • Evaluate faecal concentration of non-metabolised meloxicam 24 h post administration using HPLC method. • Investigate the reason (s) for meloxicam safety in old world vultures. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
15320456
Volume :
215
Database :
Academic Search Index
Journal :
Comparative Biochemistry & Physiology Part C: Toxicology & Pharmacology
Publication Type :
Academic Journal
Accession number :
132992830
Full Text :
https://doi.org/10.1016/j.cbpc.2018.10.001